Oncology Brothers: Practice-Changing Cancer Discussions

287 Episodes

Reverse

WCLC 2026 Highlights: MAVERICK, ADAURA, HARMONi, PAPILLON, DESTINY-Lung04 with Dr. Christine Lovly

2026-10-0519:21

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Christine Lovly, a thoracic medical oncologist from City of Hope, to discuss key studies presented at the World Conference on Lung Cancer 2026. We dived into five pivotal studies, including: MAVERICK: study on the role of MRI surveillance in small cell lung cancer (SCLC), showing that prophylactic cranial irradiation (PCI) may no longer be necessary ADAURA Update: 8-year update continues to show benefit of adjuvant osimertinib for early-stage EGFR-mutant lung cancer, with an impressive overall survival (OS) benefit HARMONi: potential of ivonescimab, a PD-1 and VEGF bispecific antibody, in the treatment of EGFR-positive disease after progression on third-generation therapies PAPILLON: discussion on the frontline treatment options for EGFR exon 20 insertion mutations, including the role of amivantamab and the anticipated approval of sunvozertinib DESTINY-Lung04: an analysis of trastuzumab deruxtecan (T-DXd) in HER2-mutated lung cancer and its implications for treatment strategies Join us as we explore the latest advancements in lung cancer treatment and the importance of biomarker testing. Don't miss this informative episode packed with insights for oncologists and healthcare professionals! Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Subscribe for more updates and discussions on the latest in oncology research and practice! #LungCancer, #WCLC2026, #Osimertinib, #Ivonescimab, #MAVERICK, #PAPILLON, #TDXd, #OncologyBrothers

Managing Toxicities of HER2+ Therapies in Upper GI Cancer - Trastuzumab, T-DXd, Zanidatamab

2026-09-3021:57

Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in HER2-targeted therapies for upper gastrointestinal malignancies, with Drs. Shruti Patel and Samuel Cytryn. Join us as we discussed: The recent approval of zanidatamab and its implications for HER2-positive esophageal and gastric adenocarcinoma The role of trastuzumab in treatment and its associated side effects, including cardiotoxicity and infusion reactions Addressing different dose used for trastuzumab deruxtecan (T-DXd) in upper GI space, along with important side effect profile to keep in mind The importance of shared decision-making in treatment options and the impact of dosing strategies on patient outcomes We also covered the critical need for biomarker-driven treatment approaches, including HER2 status and PD-L1 scores, and how these factors influence therapy choices. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Tune in for an informative discussion that bridges the gap between research and clinical practice, ensuring that patients receive the best care possible. Don't forget to like, subscribe, and hit the notification bell for more episodes! #HER2positive, #UpperGICancer, #Zanidatamab, #Trastuzumab, #TDXd, #OncologyBrothers

Upper GI Treatment Algorithm (Esophageal, Gastric, GEJ) - Dr. Sam Klempner

2026-09-2826:05

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Samuel Klempner, a GI medical oncologist from the Massachusetts General Hospital, to discuss the evolving treatment landscape for upper gastrointestinal cancers, specifically esophageal, gastroesophageal junction (GEJ), and gastric adenocarcinoma. During our discussion we touched on: The treatment algorithm for localized disease, including the shift from local therapy to a combination of systemic and local treatments The current standard of care, which includes perioperative durvalumab with the FLOT regimen and surgery The role of chemoradiation therapy for patients who are not surgical candidates and the nuances of managing residual disease The importance of biomarker-driven treatment in metastatic disease, focusing on HER2 status, PD-L1 scores, and CLDN18.2 expression The latest advancement, the approval of zanidatamab and clinical implications for treatment strategies Management of side effects associated with these therapies and the importance of patient quality of life Whether you're a healthcare professional or someone interested in the latest in cancer care, this episode provides valuable insights into the complexities of treating upper GI cancers. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #UpperGICancer, #GastricCancer, #Zanidatamab, #Zolbetuximab, #OncologyBrothers

Follicular & Mantle Cell Lymphoma Treatment Algorithm: Dr. Jonathan Friedberg

2026-09-2422:38

In this episode of the Oncology Brothers podcast, we welcomed Dr. Jonathan Friedberg, a leading lymphoma expert, to discuss modern treatment approaches for follicular lymphoma and mantle cell lymphoma. Join us as we explored: The diagnostic workup for follicular lymphoma, including the role of bone marrow biopsy and staging imaging Treatment strategies for early-stage and symptomatic follicular lymphoma, including rituximab, obinutuzumab, and chemotherapy-based approaches The evolving role of maintenance therapy and what recent studies have shown about progression-free and overall survival New treatment options in relapsed/refractory follicular lymphoma, including tafasitamab and epcoritamab The importance of TP53 testing in mantle cell lymphoma and the evolving role of BTK inhibitors in frontline treatment The role of CAR T-cell therapy and bispecific antibodies in the evolving lymphoma treatment landscape This discussion provided practical insights into current treatment algorithms and emerging strategies for patients with follicular lymphoma and mantle cell lymphoma. Whether you're a hematologist, oncologist, advanced practice provider, nurse, pharmacist, trainee, or healthcare professional interested in lymphoma care, this episode offers an expert perspective on the rapidly evolving treatment landscape. If you found this discussion valuable, please like the video, subscribe to the Oncology Brothers, and share your thoughts in the comments. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Subscribe for more expert discussions on hematology, oncology, lymphoma, immunotherapy, cellular therapy, targeted therapy, and advances in cancer care. #FollicularLymphoma #MantleCellLymphoma #Lymphoma #Hematology #OncologyBrothers

Diffuse Large B-cell Lymphoma (DLBCL) Treatment Algorithm: Dr. Mazyar Shadman

2026-09-2221:12

In this episode of the Oncology Brothers podcast we had a chance to discuss the current treatment landscape for diffuse large B-cell lymphoma (DLBCL) with Dr. Mazyar Shadman, from the Fred Hutch Cancer Center. We dived deep into frontline treatment options, including R-CHOP and polatuzumab-based regimens, and explored how to effectively risk stratify patients using the International Prognostic Index (IPI) score and the Hans algorithm. Dr. Shadman shared insights on the use of CAR T-cell therapy in both early and late relapsed settings, discussing the differences between axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and the importance of bridging and holding therapies. Key topics covered in this episode: Frontline treatment options for DLBCL The role of polatuzumab in early-stage disease Treatment paradigms for advanced-stage DLBCL CAR T-cell therapy: who should receive it and when The importance of community and tertiary care partnerships in improving patient access to innovative therapies Join us for an informative discussion that highlights the evolving landscape of DLBCL treatment and the critical role of collaboration in oncology care. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and share your thoughts in the comments! #DLBCL, #CARTtherapy, #RCHOP, #Polatuzumab, #OncologyBrothers

#box-pro-ellipsis-179145283758575{-webkit-line-clamp:2;}Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers: Practice-Changing Cancer Discussions